1. Allergan offloads two drugs to secure approval for merger with AbbVie — How the China coronavirus could threaten pharma's ingredient sourcing — AstraZeneca sees good results in gastric cancer and stroke studies — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

The blind leading the blind

Discussion in 'Blue Belt Technologies' started by Anonymous, May 7, 2013 at 10:32 AM.

  1. Anonymous

    Anonymous Guest

    Blue Belt has sold exactly two systems in the US since launching in December and another "freehand" upstart is set to stir things up. Apparently, BBT's supposedly "vast" patent moat is crumbling further. Are E.T.'s handlers at H. Capital seeing dreams of a slick buyout vaporizing? Butt ugly Frankenstein products by both. Dear gawd I hope that's a prototype and not the finished product.